Cramer: Promising data from coronavirus drug trial ‘beginning of the end of the true nightmare’

Investing

Jim Cramer

Scott Mlyn | CNBC

CNBC’s Jim Cramer said Wednesday that positive news from Gilead Sciences about a potential treatment for the coronavirus marked a turning point in the fight against Covid-19.

“What I regard this as is the beginning of the end of the true nightmare, which is that it’s a death sentence,” Cramer said on “Squawk Box.”

U.S. stocks soared on Wednesday after Gilead indicated it was seeing positive, preliminary signs about the effectiveness of its antiviral remdesivir in treating coronavirus patients.

Cramer has been hopeful about remdesivir as a possible treatment.

Last week, the “Mad Money” host said, he believes that scientists testing treatments for the coronavirus will succeed in getting patients “out of the hospital faster” and reducing “death sentence” concerns.

On Thursday, Cramer said at the time, “I do feel better about what Gilead is doing.”

Articles You May Like

‘I have no money’: Thousands of Americans see their savings vanish in Synapse fintech crisis
We’re changing our price target on TJX despite the retailer’s light guidance
New York City FC, Etihad Airways agree to 20-year naming rights deal for new MLS stadium
More young men are struggling financially. Here’s how that helped Trump win
The founder of the biggest gold ETF is still bullish 20 years later

Leave a Reply

Your email address will not be published. Required fields are marked *